Transplantation and Cellular Therapy Meetings

Premal Lulla, MD, discusses the need for cellular therapies for patients with leukemia after transplant.

Sergio A. Giralt, MD, discusses the role of allogeneic hematopoietic cell therapy in patients with multiple myeloma.

Christopher E. Dandoy, MD, MSc, says that patients undergoing allogenic stem cell transplant are at high-risk of developing thrombotic microangiopathy.

Christopher E. Dandoy, MD, MSc, discussed how higher levels of soluble suppression of tumorigenicity-2 and soluble terminal complement complex were associated with high-risk thrombotic microangiopathy, a severe complication related to stem cell transplantation.

Transplant-associated thrombotic microangiopathy occurred in as many as 36% of hematopoietic cell transplants and significantly increased the risk of transplant-related mortality.

Richard E. Champlin, MD, a professor of medicine at MD Anderson Cancer Center, discusses the association seen between the Endothelial Activation and Stress Index (EASIX) and fluid overload and survival in patients who underwent an allogenic stem cell transplantation.

Shaji Kumar, MD, of Mayo Clinic, advises physicians on the use of autologous stem cell transplant in patients with newly diagnosed multiple myeloma.

Frederick L. Locke, MD, discusses the optimal management of chimeric antigen receptor T-cell therapy-related adverse events.

Patients with relapsed/refractory chronic lymphocytic leukemia had an improved response rate with chimeric antigen receptor T-cell therapy if they also received ibrutinib.

Adults with acute lymphoblastic leukemia had worse outcomes, including lower survival, after myeloablative allogeneic transplantation if they remained positive for minimal residual disease at the time of transplant.

Gareth Morgan, MD, discusses the TOURMALINE-MM3 findings in multiple myeloma and other clinical trials that are impacting the landscape for this patient population.

Axicabtagene ciloleucel had an objective response rate of 76% and a complete response rate of 47% in patients with aggressive non-Hodgkin lymphoma followed for at least 1 month.

Prophylactic treatment with letermovir lowered the rates of cytomegalovirus infection and all-cause mortality compared with placebo for CMV-seropositive patients following an allogeneic hematopoietic stem cell transplant.

Vorinostat combined with tacrolimus and methotrexate represents a potentially effective combination to mitigate graft-versus-host disease in the setting of matched unrelated donor myeloablative conditioning hematopoietic stem cell transplant.

Francisco Marty, MD, Dana-Farber Cancer Institute, discusses the initial results of the Phase III trial evaluating letermovir for CMV after bone marrow transplant.

Proper care coordination and patient education are essential to the success of delivering chimeric antigen receptor T-cell therapy, particularly in preparing patients for potential adverse events.

A host of new and emerging therapies for acute and chronic graft-versus-host disease are on the horizon and include B-cell depletion, IL-2, inhibitors of JAK1/JAK2, extracorporeal photopheresis, and the BTK inhibitor ibrutinib.

Sergio A. Giralt, MD, reviewed emerging strategies to improve stem cell transplantation outcomes by reducing the risk of relapse using novel drugs and targeted radiotherapy.

Fred Locke, MD, Moffitt Cancer Center discusses the interim results of the ZUMA-I trial of Kte-C19, a CAR T-cell therapy.

Bart Scott, MD, Fred Hutchinson Cancer Research Center, explains the importance of the intensity of conditioning for stem cell transplants.

Robert Korngold, PhD, John Theurer Cancer Center looks back on the advances we've made so far in bone marrow transplant.

Treatment with an inactivated varicella zoster virus vaccine, known as V212, lowered the cumulative incidence rate of herpes zoster infection and complications for patients undergoing autologous hematopoietic stem cell transplantation.

Rates of early relapse post-autologous stem cell transplant in patients with relapsing multiple myeloma have not changed over time, but post-relapse survival among early relapsers has improved for patients transplanted after 2005 and for those relapsing since 2008.

Dr. Lancet of Moffitt Cancer Center explains the use of CPX-351 treatment compared to induction chemotherapy, for older adult patients with acute myeloid leukemia.

Partow Kebriaei, MD, discusses the Iomab-B clinical trial for older patients with acute myeloid leukemia.

According to data from a phase I/II clinical trial, carfilzomib can be safely combined with melphalan in a conditioning regimen prior to autologous hematopoietic cell transplantation in patients with relapsed multiple myeloma.

More patients with acute myeloid leukemia could proceed to transplant following treatment with CPX-351 compared with the traditional 7+3 chemotherapy regimen.